U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Safety
  3. Recalls, Market Withdrawals, & Safety Alerts
  4. Innoveix Pharmaceuticals, Inc. Issues Voluntary Recall of all Sterile Compounded Drug Products Due to a Lack of Sterility Assurance
  1. Recalls, Market Withdrawals, & Safety Alerts

COMPANY ANNOUNCEMENT

Innoveix Pharmaceuticals, Inc. Issues Voluntary Recall of all Sterile Compounded Drug Products Due to a Lack of Sterility Assurance

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Read Announcement

Summary

Company Announcement Date:
FDA Publish Date:
Product Type:
Drugs
Reason for Announcement:
Recall Reason Description
Potential lack of sterility assurance
Company Name:
Innoveix Pharmaceuticals, Inc.
Brand Name:
Brand Name(s)
Innoveix Pharmaceuticals, Inc.
Product Description:
Product Description
Injectable Human Chorionic Gonadotropin (HCG) and injectable Sermorelin w/GHRP2

Company Announcement

Innoveix Pharmaceuticals, Inc. is voluntarily recalling all sterile compounded drug products, within expiry, to the consumer level. The products are being recalled due to a lack of assurance of sterility. These concerns arose following a routine inspection of the pharmacy by FDA.

Administration of a drug product intended to be sterile, that is not sterile, could result in serious infections which may be life-threatening. To date, Innoveix Pharmaceuticals, Inc. has not received any reports of adverse events related to this recall. This voluntary recall is being conducted out of an abundance of caution and to promote patient safety, which is the pharmacy's highest priority.

The affected products are injectable Human Chorionic Gonadotropin (HCG) and injectable Sermorelin w/GHRP2. The products can be used for various indications as prescribed. The products can be identified by an Innoveix Pharmaceuticals, Inc. label. Products were distributed to both customers and/or medical facilities. A full list of the affected products with the applicable lot numbers and expiration dates is as follows:

Product Lot/Expiry
HCG 11,000 IUs Lot # INX 530; Exp: 11/9/18 to 11/6/19 Lot # INX 535; Exp: 11/21/18 to 11/15/19 Lot # INX 540; Exp: 2/20/19 to 2/1/20 Lot # INX 555; Exp: 4/9/19 to 3/26/20 Lot # INX 550; Exp: 3/22/19 to 3/9/20 Lot # INX 555; Exp: 4/9/19 to 3/26/20 Lot # INX 560; Exp: 5/9/19 to 5/3/20 Lot # INX 565; Exp: 6/12/19 to 5/18/20 Lot # INX 570; Exp: 6/28/19 to 6/28/20 Lot # INX 575; Exp: 7/26/19 to 7/18/20
HCG 5,000 IU's Lot # INX 910; Exp: 2/20/19 to 2/7/20 Lot # INX 915; Exp: 3/22/19 to 3/12/20
HCG 5,500 IU's Lot # INX 50; Exp: 5/9/19 to 5/1/20
Sermorelin w/GHRP2 3mg Lot # SER 925; Exp: 11/19/18 to 11/4/19 Lot # SER 930; Exp: 2/22/19 to 11/18/19 Lot # SER 935; Exp: 3/5/19 to 2/21/20 Lot # SER 400; Exp: 4/29/19 to 4/1/20 Lot # SER 405; Exp: 6/3/19 to 5/11/20
Lot # SER 410; Exp: 7/23/19 to 7/15/20

The pharmacy has notified potentially affected customers of the voluntary recall via U.S. Mail and direct outreach. Customers who have received sterile compounded products subject to the voluntary recall should not use them and return the product to the pharmacy for a full refund.

Consumers with questions regarding this recall can contact Innoveix Pharmaceuticals, Inc. by phone 800-370-1910 or innoveix@gmail.com. We are available Monday through Friday from 9 AM to 4:30 PM CST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company Contact Information

Consumers:
Innoveix Pharmaceuticals
800-370-1910
innoveix@gmail.com
Media:
Kevin Hogan
214-390-3371
Back to Top